- Home
- NVGS vs MLYS Comparison
NVGS vs MLYS Comparison
Compare NVGS & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVGS | MLYS |
|---|---|---|
| Founded | 1997 | 2019 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 3.1B |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | NVGS | MLYS |
|---|---|---|
| Price | $17.54 | $36.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $21.50 | ★ $46.40 |
| AVG Volume (30 Days) | 310.8K | ★ 1.6M |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | ★ 1.60% | N/A |
| EPS Growth | ★ 33.99 | N/A |
| EPS | ★ 1.50 | N/A |
| Revenue | ★ $578,158,000.00 | N/A |
| Revenue This Year | $2.77 | N/A |
| Revenue Next Year | $0.18 | N/A |
| P/E Ratio | $11.54 | ★ N/A |
| Revenue Growth | ★ 2.46 | N/A |
| 52 Week Low | $10.55 | $8.24 |
| 52 Week High | $18.29 | $47.65 |
Technical Indicators
Market Signals| Indicator | NVGS | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 53.55 | 40.09 |
| Support Level | $17.20 | $35.77 |
| Resistance Level | $18.07 | $44.13 |
| Average True Range (ATR) | 0.35 | 1.93 |
| MACD | -0.12 | -0.64 |
| Stochastic Oscillator | 37.00 | 14.95 |
Price Performance
Historical ComparisonAbout NVGS Navigator Holdings Ltd. (Marshall Islands)
Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture). Company play a vital role in theglobalised liquefied gas supply chain, providing gas transportation solutions for energy companies, industrial users and commodity traders.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.